In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 167, 105528
Abstract
No abstract availableKeywords
Funding Information
- American Society of Hematology
- National Institutes of Health
This publication has 50 references indexed in Scilit:
- Statins inhibit proliferation and cytotoxicity of a human leukemic natural killer cell lineBiomarker Research, 2013
- Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferasesJournal of Lipid Research, 2012
- Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastomaJournal of Experimental & Clinical Cancer Research, 2011
- Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cellsLeukemia Research, 2011
- A Novel Geranylgeranyl Transferase Inhibitor in Combination with Lovastatin Inhibits Proliferation and Induces Autophagy in STS-26T MPNST CellsThe Journal of Pharmacology and Experimental Therapeutics, 2010
- In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-IMolecular Cancer Therapeutics, 2009
- Geranylgeranyl transferase type II inhibition prevents myeloma bone diseaseBiochemical and Biophysical Research Communications, 2008
- Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task ForceThe American Journal of Cardiology, 2006
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and LovastatinThe Journal of Clinical Pharmacology, 1990